1. Home
  2. CMMB vs SGLY Comparison

CMMB vs SGLY Comparison

Compare CMMB & SGLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CMMB
  • SGLY
  • Stock Information
  • Founded
  • CMMB 2004
  • SGLY 2001
  • Country
  • CMMB Israel
  • SGLY United States
  • Employees
  • CMMB N/A
  • SGLY N/A
  • Industry
  • CMMB Biotechnology: Pharmaceutical Preparations
  • SGLY
  • Sector
  • CMMB Health Care
  • SGLY
  • Exchange
  • CMMB Nasdaq
  • SGLY Nasdaq
  • Market Cap
  • CMMB 22.0M
  • SGLY 3.9M
  • IPO Year
  • CMMB N/A
  • SGLY 2008
  • Fundamental
  • Price
  • CMMB $1.13
  • SGLY $1.01
  • Analyst Decision
  • CMMB Strong Buy
  • SGLY
  • Analyst Count
  • CMMB 2
  • SGLY 0
  • Target Price
  • CMMB $8.50
  • SGLY N/A
  • AVG Volume (30 Days)
  • CMMB 187.2K
  • SGLY 48.0K
  • Earning Date
  • CMMB 08-20-2025
  • SGLY 08-26-2025
  • Dividend Yield
  • CMMB N/A
  • SGLY N/A
  • EPS Growth
  • CMMB N/A
  • SGLY N/A
  • EPS
  • CMMB N/A
  • SGLY N/A
  • Revenue
  • CMMB N/A
  • SGLY $2,172,036.00
  • Revenue This Year
  • CMMB N/A
  • SGLY N/A
  • Revenue Next Year
  • CMMB N/A
  • SGLY N/A
  • P/E Ratio
  • CMMB N/A
  • SGLY N/A
  • Revenue Growth
  • CMMB N/A
  • SGLY N/A
  • 52 Week Low
  • CMMB $0.87
  • SGLY $0.54
  • 52 Week High
  • CMMB $2.55
  • SGLY $7.65
  • Technical
  • Relative Strength Index (RSI)
  • CMMB 42.55
  • SGLY 49.45
  • Support Level
  • CMMB $1.17
  • SGLY $0.93
  • Resistance Level
  • CMMB $1.23
  • SGLY $1.05
  • Average True Range (ATR)
  • CMMB 0.05
  • SGLY 0.07
  • MACD
  • CMMB 0.00
  • SGLY -0.01
  • Stochastic Oscillator
  • CMMB 34.11
  • SGLY 30.64

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

About SGLY Singularity Future Technology Ltd.

Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.

Share on Social Networks: